Walgreens Teams With Microsoft as Both Wrestle Amazon Threats
Drugmakers Defend Practices as Washington Girds for Price Fight
Drugmaker Won't Put Price in TV Ads, But Patients Can Look It Up
Health Titans Converge on San Francisco With DNA and Deals on Tap
Shareholders from Celgene and Bristol-Myers will have to approve the deal, and there are early signs they have doubts.
Celgene shareholders will get one Bristol-Myers Squibb share and $50 in cash for each Celgene share held.
Activist Pushing Cancer Drugmaker Clovis to Pursue Sale
Pitocin and Ketamine Prices Are Surging as Shortages Drag On
Pharma giants have been quick to tout their efforts to help the Trump administration rein in runaway drug prices.
Mylan's Beat Lifts Hopes That Worst Is Over for Generic Makers
Investors have mostly been willing to hold their nose over Hospira as Pfizer’s stock surged this year.
Pfizer Narrows Forecast as Its Older Drugs Business Struggles
Merck and Bristol-Myers Cancer Race Could Turn Into Deals Derby
Merck Plans $10 Billion Buyback as Cancer Drug Tops Views
Drug Lobby Sets Stage for Free-Speech Battle Over Prices in Ads
Pfizer Veteran Bourla to Take Over CEO Role From Ian Read
Trump Eyeing ‘Disruptive’ Changes to Drug Pricing, Health Secretary Says
Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching
Generic Drugmakers Struggle Despite U.S. Push for Copycats
Mylan Plans Strategic Review as North American Sales Plummet
U.S Federal Trade Commission indicated it wants Germany’s Linde AG, Praxair Inc. to sell more assets before approving deal.